PE20231029A1 - ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO - Google Patents
ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMOInfo
- Publication number
- PE20231029A1 PE20231029A1 PE2022002215A PE2022002215A PE20231029A1 PE 20231029 A1 PE20231029 A1 PE 20231029A1 PE 2022002215 A PE2022002215 A PE 2022002215A PE 2022002215 A PE2022002215 A PE 2022002215A PE 20231029 A1 PE20231029 A1 PE 20231029A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- amino acid
- nos
- acid sequence
- heavy chain
- Prior art date
Links
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 title abstract 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 title abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 10
- 208000018737 Parkinson disease Diseases 0.000 abstract 3
- 206010067889 Dementia with Lewy bodies Diseases 0.000 abstract 2
- 201000002832 Lewy body dementia Diseases 0.000 abstract 2
- 208000001089 Multiple system atrophy Diseases 0.000 abstract 2
- 102000003802 alpha-Synuclein Human genes 0.000 abstract 2
- 108090000185 alpha-Synuclein Proteins 0.000 abstract 2
- 206010012289 Dementia Diseases 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000008499 blood brain barrier function Effects 0.000 abstract 1
- 210000001218 blood-brain barrier Anatomy 0.000 abstract 1
- 210000004556 brain Anatomy 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 210000004558 lewy body Anatomy 0.000 abstract 1
- 210000002569 neuron Anatomy 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Esta referida a un anticuerpo anti-IGF1R o un fragmento de union a antigeno del mismo que comprende una region variable de cadena pesada y una region variable de cadena ligera, en el que la region variable de cadena pesada comprende una CDR1 de cadena pesada (H-CDR1) que comprende una secuencia de aminoacidos seleccionada de las secuencias de aminoacidos de SEQ ID NO: 1 y SEQ ID NO: 10, una CDR2 de cadena pesada (H-CDR2) que comprende una secuencia de aminoacidos seleccionada de las secuencias de aminoacidos de SEQ ID NOs: 2 a 7 y SEQ ID NOs: 11 a 18, y una CDR3 de cadena pesada (H-CDR3) que comprende una secuencia de aminoacidos seleccionada de las secuencias de aminoacidos de SEQ ID NOs: 8 a 9 y SEQ ID NO: 19, y la region variable de cadena ligera comprende una CDR1 de cadena ligera (L-CDR1) que comprende una secuencia de aminoacidos de SEQ ID NO: 20, una CDR2 de cadena ligera (L-CDR2) que comprende una secuencia de aminoacidos seleccionada de las secuencias de aminoacidos de SEQ ID NOs: 21 a 23, y una CDR3 de cadena ligera (L-CDR3) que comprende una secuencia de aminoacidos seleccionada de las secuencias de aminoacidos de SEQ ID NOs: 24 a 28 y SEQ ID NOs: 29 a 31. Este anticuerpo es un anticuerpo biespecifico que se une especificamente a alfa-sinucleina e IGF1R y puede permitir que el anticuerpo penetre la barrera hematoencefalica para ejercer su accion en el cerebro y prolongar la semivida para mantener la eficacia durante mucho tiempo. Se sabe que estos agregados de alfa-sinucleina inducen toxicidad a las celulas, y son el principal componente de un agregado proteico anomalo de cuerpos de Lewy que se hallan en neuronas de enfermedad de Parkinson (PD), demencia por enfermedad de Parkinson (PDD), atrofia multisistemica (MSA), demencia con cuerpos de Lewy (DLB) y diversas enfermedades.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190071057 | 2019-06-14 | ||
| PCT/KR2020/007704 WO2020251316A1 (ko) | 2019-06-14 | 2020-06-15 | α-SYN/IGF1R에 대한 이중 특이 항체 및 그 용도 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231029A1 true PE20231029A1 (es) | 2023-07-10 |
Family
ID=73781866
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002215A PE20231029A1 (es) | 2019-06-14 | 2020-06-15 | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO |
| PE2021002067A PE20220516A1 (es) | 2019-06-14 | 2020-06-15 | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021002067A PE20220516A1 (es) | 2019-06-14 | 2020-06-15 | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20220348665A1 (es) |
| EP (2) | EP3985022A4 (es) |
| JP (3) | JP7348676B2 (es) |
| KR (2) | KR20220044397A (es) |
| CN (2) | CN113966346A (es) |
| AU (2) | AU2020291487A1 (es) |
| BR (1) | BR112021025086A2 (es) |
| CA (1) | CA3143242A1 (es) |
| CL (1) | CL2021003335A1 (es) |
| CO (1) | CO2021017688A2 (es) |
| EA (1) | EA202193058A1 (es) |
| IL (2) | IL302490A (es) |
| MX (2) | MX2021015081A (es) |
| PE (2) | PE20231029A1 (es) |
| WO (1) | WO2020251316A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7136790B2 (ja) | 2017-02-17 | 2022-09-13 | ブリストル－マイヤーズ スクイブ カンパニー | アルファ－シヌクレインに対する抗体およびその使用 |
| KR20240031229A (ko) * | 2021-05-12 | 2024-03-07 | 에이비엘바이오 주식회사 | 알파-시누클레인병증 치료용 항체 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US6342220B1 (en) | 1997-08-25 | 2002-01-29 | Genentech, Inc. | Agonist antibodies |
| NZ589434A (en) * | 2008-06-03 | 2012-11-30 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
| BR112014010198B1 (pt) * | 2011-10-28 | 2022-12-06 | Prothena Biosciences Limited | Anticorpos humanizados que reconhecem alfa-sinucleína |
| US9534044B2 (en) * | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| WO2015031673A2 (en) * | 2013-08-28 | 2015-03-05 | Bioasis Technologies Inc. | Cns-targeted conjugates having modified fc regions and methods of use thereof |
| US11191832B2 (en) * | 2013-11-19 | 2021-12-07 | Prothena Biosciences Limited | Monitoring immunotherapy of Lewy body disease from constipation symptoms |
| KR102355309B1 (ko) * | 2014-03-06 | 2022-01-24 | 내셔날 리서치 카운실 오브 캐나다 | 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도 |
| EA035480B1 (ru) * | 2014-03-06 | 2020-06-23 | Нэшнл Рисеч Каунсил Оф Канада | Антитела, специфические к рецептору инсулиноподобного фактора роста 1 и их применения |
| EP3114142B1 (en) * | 2014-03-06 | 2019-06-05 | National Research Council of Canada | Insulin-like growth factor 1 receptor -specific antibodies and uses thereof |
| EP3207057A2 (en) * | 2014-10-16 | 2017-08-23 | F. Hoffmann-La Roche AG | Anti-alpha-synuclein antibodies and methods of use |
| KR20180100238A (ko) * | 2016-01-22 | 2018-09-07 | 얀센 바이오테크 인코포레이티드 | 항-ror1 항체, ror1 × cd3 이중특이성 항체, 및 이를 사용하는 방법 |
| JP6908709B2 (ja) | 2017-01-06 | 2021-07-28 | エービーエル バイオ インコーポレイテッド | 抗α−ｓｙｎ抗体およびその使用 |
| KR102236259B1 (ko) * | 2017-02-22 | 2021-04-06 | 아이-맵 바이오파마 유에스 리미티드 | 항-lag-3 항체 및 그것의 사용 |
| EP3625258A1 (en) * | 2017-05-16 | 2020-03-25 | Alector LLC | Anti-siglec-5 antibodies and methods of use thereof |
| EP3661961A4 (en) * | 2017-08-02 | 2021-04-14 | Stressmarq Biosciences Inc. | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN |
| MX2020004674A (es) * | 2017-11-17 | 2020-08-13 | Abl Bio Inc | Anticuerpos contra alfa-sinucleina y usos de los mismos. |
| CA3085572A1 (en) * | 2017-12-14 | 2019-06-20 | Abl Bio Inc. | Bispecific antibody to a-syn/igf1r and use thereof |
-
2020
- 2020-06-15 CN CN202080043719.7A patent/CN113966346A/zh active Pending
- 2020-06-15 BR BR112021025086A patent/BR112021025086A2/pt unknown
- 2020-06-15 EP EP20822425.3A patent/EP3985022A4/en active Pending
- 2020-06-15 EA EA202193058A patent/EA202193058A1/ru unknown
- 2020-06-15 EP EP23178097.4A patent/EP4268842A3/en active Pending
- 2020-06-15 KR KR1020227010688A patent/KR20220044397A/ko active IP Right Grant
- 2020-06-15 WO PCT/KR2020/007704 patent/WO2020251316A1/ko active Application Filing
- 2020-06-15 IL IL302490A patent/IL302490A/en unknown
- 2020-06-15 US US17/616,799 patent/US20220348665A1/en active Pending
- 2020-06-15 KR KR1020217018648A patent/KR102444797B1/ko active IP Right Grant
- 2020-06-15 AU AU2020291487A patent/AU2020291487A1/en active Pending
- 2020-06-15 CA CA3143242A patent/CA3143242A1/en active Pending
- 2020-06-15 CN CN202310652804.9A patent/CN117024589A/zh active Pending
- 2020-06-15 MX MX2021015081A patent/MX2021015081A/es unknown
- 2020-06-15 PE PE2022002215A patent/PE20231029A1/es unknown
- 2020-06-15 JP JP2021573848A patent/JP7348676B2/ja active Active
- 2020-06-15 PE PE2021002067A patent/PE20220516A1/es unknown
-
2021
- 2021-12-05 IL IL288692A patent/IL288692A/en unknown
- 2021-12-07 MX MX2023006669A patent/MX2023006669A/es unknown
- 2021-12-13 CL CL2021003335A patent/CL2021003335A1/es unknown
- 2021-12-22 CO CONC2021/0017688A patent/CO2021017688A2/es unknown
-
2022
- 2022-12-08 US US18/063,550 patent/US20230357412A1/en active Pending
-
2023
- 2023-04-13 JP JP2023065309A patent/JP2023113599A/ja active Pending
- 2023-04-28 AU AU2023202595A patent/AU2023202595A1/en active Pending
- 2023-09-01 JP JP2023141925A patent/JP2023179442A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3143242A1 (en) | 2020-12-17 |
| EP3985022A4 (en) | 2023-08-02 |
| CO2021017688A2 (es) | 2022-01-17 |
| EP4268842A3 (en) | 2024-05-22 |
| CL2021003335A1 (es) | 2022-07-15 |
| CN113966346A (zh) | 2022-01-21 |
| EP4268842A2 (en) | 2023-11-01 |
| MX2023006669A (es) | 2023-06-21 |
| EA202193058A1 (ru) | 2022-03-05 |
| PE20220516A1 (es) | 2022-04-07 |
| BR112021025086A2 (pt) | 2022-01-25 |
| AU2020291487A1 (en) | 2022-01-20 |
| KR102444797B1 (ko) | 2022-09-20 |
| MX2021015081A (es) | 2022-01-18 |
| CN117024589A (zh) | 2023-11-10 |
| JP2023179442A (ja) | 2023-12-19 |
| US20230357412A1 (en) | 2023-11-09 |
| JP2022537279A (ja) | 2022-08-25 |
| AU2023202595A1 (en) | 2023-06-29 |
| US20220348665A1 (en) | 2022-11-03 |
| JP7348676B2 (ja) | 2023-09-21 |
| KR20220044397A (ko) | 2022-04-07 |
| IL302490A (en) | 2023-06-01 |
| JP2023113599A (ja) | 2023-08-16 |
| EP3985022A1 (en) | 2022-04-20 |
| WO2020251316A1 (ko) | 2020-12-17 |
| IL288692A (en) | 2022-02-01 |
| KR20210087093A (ko) | 2021-07-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR072985A1 (es) | Tratamiento para una enfermedad autoinmune o trastorno inflamatorio, procedimiento, anticuerpo, proteina de union | |
| CY1123212T1 (el) | Συνθεσεις για την αναστολη της ενεργοποιησης του masp-2 εξαρτωμενου συμπληρωματος | |
| HRP20211935T1 (hr) | Protutijela anti-alfa-sinuklein i njihove uporabe | |
| RU2014108047A (ru) | Фармацевтическая композиция для лечения и/или профилактики рака поджелудочной железы | |
| CO6430469A2 (es) | Anticuerpos humanizados que se unen a cd19 y sus usos | |
| CL2008003004A1 (es) | Anticuerpo anti-esclerostina o su porción de enlace de antígeno; polinucleotido que lo codifica; vector; célula; proceso de producción; composición farmacéutica que lo comprende; método para identificar células y su uso para tratar trastornos óseos. | |
| RU2011108260A (ru) | Фармацевтическая композиция для лечения и профилактики злокачественных опухолей | |
| PE20231029A1 (es) | ANTICUERPO BIESPECIFICO CONTRA (alfa)-SYN/IGF1R Y USO DEL MISMO | |
| PE20120343A1 (es) | Anticuerpo anti-cmet que comprende una region bisagra | |
| AR109715A1 (es) | Anticuerpos anti-cd27 | |
| PE20120816A1 (es) | Composiciones que comprenden anticuerpos de dickkopf-1 | |
| PE20142041A1 (es) | Anticuerpos anti-il-36r | |
| NZ585559A (en) | Humanized antibodies against tl1a | |
| PE20020574A1 (es) | Anticuerpos humanizados que reconocen el peptido amiloideo beta | |
| AR065506A1 (es) | Anticuerpos antagonistas ox40 y su uso en el tratamiento de enfermedades | |
| AR040046A1 (es) | Anticuerpo neutralizante humano anti-igfr | |
| US20120231006A1 (en) | Anti-orai1 antigen binding proteins and uses thereof | |
| AR069130A1 (es) | Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento | |
| EA202090800A1 (ru) | Новые анти-cd3-эпсилон антитела | |
| CL2008003089A1 (es) | Metodo para tratar enfermedad de alzheimer que comprende un regimen de un anticuerpo que se un epitopo en el n-terminal del peptido amiloide beta, anticuerpo humanizado contra la proteina amiloide beta que tiene sustituidas las posiciones 234, 235, y 237 por alanina en la region constante de las cadenas pesadas. | |
| AR107290A1 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| AR109533A2 (es) | Anticuerpos anti-fractalkina o un fragmento de unión a la fkn de éste, composiciones que lo comprenden y métodos para tratar trastornos inflamatorios | |
| PE20181051A1 (es) | Anticuerpo anti-epha4 | |
| PE20220708A1 (es) | Anticuerpos anti-cd73 | |
| PE20191075A1 (es) | Anticuerpo que se une especificamente a il-17a y fragmento funcional del mismo |